Search hospitals > Oregon > Portland
Providence Portland Medical Center
Claim this profilePortland, Oregon 97213
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Melanoma
578 reported clinical trials
37 medical researchers
Summary
Providence Portland Medical Center is a medical facility located in Portland, Oregon. This center is recognized for care of Lung Cancer, Breast Cancer, Cancer, Non-Small Cell Lung Cancer, Melanoma and other specialties. Providence Portland Medical Center is involved with conducting 578 clinical trials across 571 conditions. There are 37 research doctors associated with this hospital, such as Alison K. Conlin, Charles W. Drescher, Rachel Sanborn, MD, and Nitya Alluri.Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
EGFR positive
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Alison K. ConlinProvidence Portland Medical Center6 years of reported clinical research
Expert in Breast Cancer
Expert in Cancer
107 reported clinical trials
183 drugs studied
Charles W. DrescherProvidence Portland Medical Center8 years of reported clinical research
Studies Breast Cancer
Studies Non-Small Cell Lung Cancer
53 reported clinical trials
99 drugs studied
Rachel Sanborn, MDProvidence Portland Medical Center6 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
43 reported clinical trials
68 drugs studied
Nitya AlluriProvidence Portland Medical Center2 years of reported clinical research
Studies Uterine Cancer
Studies Endometrial Adenocarcinoma
28 reported clinical trials
79 drugs studied
Clinical Trials running at Providence Portland Medical Center
Lung Cancer
Breast Cancer
Breast cancer
Prostate Cancer
Pancreatic Cancer
Ovarian Cancer
Esophageal cancer
Esophageal Cancer
Multiple Myeloma
Kidney Cancer
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Durvalumab
for Lung Cancer
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients who are not in a study is to closely watch a patient's condition after surgery and to have regular visits with their doctor to watch for signs of the cancer coming back. Usually, patients do not receive further treatment unless the cancer returns. This study will help determine whether this different approach with durvalumab is better, the same, or worse than the usual approach of observation. Giving durvalumab may help patients live longer and prevent early-stage non-small cell lung cancer from coming back as compared to the usual approach.
Recruiting2 awards Phase 38 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Providence Portland Medical Center?
Providence Portland Medical Center is a medical facility located in Portland, Oregon. This center is recognized for care of Lung Cancer, Breast Cancer, Cancer, Non-Small Cell Lung Cancer, Melanoma and other specialties. Providence Portland Medical Center is involved with conducting 578 clinical trials across 571 conditions. There are 37 research doctors associated with this hospital, such as Alison K. Conlin, Charles W. Drescher, Rachel Sanborn, MD, and Nitya Alluri.
Where is Providence Portland Medical Center located?
**Providence Portland Medical Center**
- **Address:** 4805 NE Glisan St, Portland, OR 97213
- **Accessibility:** Easily accessible via public transit, including bus and light rail options.
- **Specialties:** Renowned for excellence in cancer, heart, orthopedics, women's health, rehabilitation services, and behavioral health.
Who should I call to ask about financial aid or insurance network?
For financial assistance at Providence Portland Medical Center:
- Contact financial counselors at **855-229-6466**, available Monday – Friday, 7 a.m. to 5:30 p.m. PT.
- For billing inquiries related to Providence Hospitals & Clinics, call **866-747-2455** (toll-free) or **503-574-5791** (local - Portland metro area).
- For billing inquiries related to Providence Health Plan, call **800-878-4445** (toll-free) or **503-574-5791** (local - Portland metro area).
What insurance does Providence Portland Medical Center accept?
Providence Portland Medical Center accepts a wide range of health plans, including Aetna, Blue Cross Blue Shield, Cigna, Coventry, First Health, Humana, MultiPlan, Private Healthcare Systems (PHCS), TRICARE for Life, United Healthcare, and more. The hospital also accepts various Medicare and Medicaid plans, alongside commercial/indemnity insurance plans. For the most accurate information regarding coverage, please check directly with your insurance provider and the hospital.
What awards or recognition has Providence Portland Medical Center received?
Providence Portland Medical Center, located in Portland, Oregon, has been awarded a Health Care Innovation Award of $17,337,093 for transforming the delivery system of Oregon's largest Medicaid Coordinated Care Organization (CCO). This initiative focuses on enhancing care coordination, quality, and outcomes for high-cost, high-acuity Medicaid patients while aiming to reduce overall health care costs. The hospital is renowned for its excellence in patient care and research, particularly in cancer, heart, orthopedics, women's health, rehabilitation services, and behavioral health, and holds the prestigious Magnet® designation for nursing excellence.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.